| answer text |
<p>All United Kingdom marketing authorisation holders of liothyronine are obliged
to ensure that the product complies with the minimum standard as specified in the
updated British Pharmacopoeia monograph for liothyronine tablets. Liothyronine on
the market in other European Union Member States may not comply with the updated British
Pharmacopoeia monograph and therefore would not be considered therapeutically equivalent.</p><p>Liothyronine
is an unbranded generic medicine. The Department encourages competition between suppliers
of unbranded generic medicines to keep prices down. This generally works well and
has led to some of the lowest prices in Europe. Concerns about anti-competitive behaviour
are a matter for the Competition and Markets Authority (CMA) to investigate.</p><p>Liothyronine,
marketed by Advanz Pharma (formerly Concordia), is currently the subject of an investigation
by the CMA. The CMA has provisionally found that the company abused its dominant position
to overcharge the National Health Service by millions of pounds for liothyronine tablets.
A provisional decision does not necessarily lead to an infringement decision. Where
companies have breached competition law, the Department will seek damages and invest
that money back into the NHS.</p>
|
|
